Pain and QoL Data Presented for Gore’s Viabahn Fortegra Venous Stent

April 22, 2026—Gore & Associates announced new 12-month findings from the global GORE VIABAHN FORTEGRA Venous Stent IVC trial, which evaluated treatment of patients with symptomatic deep venous iliocaval obstruction.

Sonorous BosCath Neurovascular Catheter Cleared by FDA

April 22, 2026—Sonorous Neurovascular, a developer of solutions for cerebral venous diseases and neurovascular interventions, announced that it has received FDA 510(k) clearance for its BosCath, allowing the company to commercialize the next-generation neurovascular catheter in the United States.

Data Presented From Pilot Trial of InVera Infusion Device for Chronic Venous Disease 

April 21, 2026—InVera Medical announced 12-month results from its pilot clinical study of the InVera infusion device for the treatment of chronic venous disease (CVD).

Penumbra’s CAVT Evaluated in 90-Day STORM-PE Data

April 13, 2026—Penumbra, Inc. announced 90-day results of the STORM-PE randomized controlled trial (RCT) that is evaluating computer-assisted vacuum thrombectomy (CAVT) using Penumbra’s Lightning Flash device plus anticoagulation versus anticoagulation alone for the treatment of patients with acute intermediate-high risk pulmonary embolism (PE).

C-TRACT Evaluates Endovascular Therapy to Treat Postthrombotic Syndrome After DVT 

April 13, 2026—The Society of Interventional Radiology (SIR) announced results from the C-TRACT study, which is investigating the treatment of postthrombotic syndrome (PTS) after deep vein thrombosis (DVT).

BD’s Liverty TIPS Stent Graft Receives CE Mark Approval in Europe

April 10, 2026—BD (Becton, Dickinson and Company) announced European CE Mark approval for the Liverty transjugular intrahepatic portosystemic shunt (TIPS) stent graft.

FDA Clears InVera Infusion Device to Treat Chronic Venous Disease

April 8, 2026—InVera Medical announced FDA 510(k) clearance for the InVera infusion device for the minimally invasive treatment of diseased leg veins, including varicose veins.

Embolization, Inc.’s Polymer-Based NED Coil Evaluated in Limited-Market Release 

April 7, 2026—Embolization, Inc. announced findings from the limited-market release of the company’s nitinol enhanced device (NED), which is a radiopaque, polymer-based embolic coil.

Baylis Launches PowerWire 14 RF Guidewire to Treat Arterial and Venous Occlusions

April 7, 2026—Baylis Medical Technologies Inc. announced FDA 510(k) clearance and the commercial launch of the company’s PowerWire 14 radiofrequency (RF) guidewire, which is intended for use in both arterial and venous occlusions.

HI-PEITHO: Boston Scientific’s Ekos System Superior to Anticoagulation Alone in Acute Intermediate-Risk PE

March 28, 2026—Boston Scientific Corporation announced that the HI-PEITHO global randomized clinical trial evaluating the use of the Ekos endovascular system in patients with intermediate-risk pulmonary embolism (PE) met the composite primary endpoint.

Imperative Care Launches CLEAR-IT Peripheral Thromboembolism Study

March 25, 2025—Imperative Care, Inc. announced the enrollment of the first patient in the prospective observational CLEAR-IT clinical study evaluating the performance of the company’s Symphony and Prodigy systems, which are aspiration-based technologies used in endovascular thrombectomy procedures across the peripheral and pulmonary vasculature.

Imperative Care’s Stroke and Vascular Thrombectomy Portfolio Supported by New Financing

March 18, 2026—Imperative Care, Inc., a developer of treatments for thromboembolic disease, announced the closing of a $100 million convertible note financing.

Thrombolex Secures Financing for Commercialization of Bashir Catheters for Pulmonary Embolism Treatment

March 17, 2026—Thrombolex, Inc., a commercial-stage developer of a differentiated pharmacomechanical lysis platform for the treatment of pulmonary embolism and other thromboembolic diseases, announced the closing of a $50 million Series A equity financing led by OrbiMed and supported by current investors and cofounders.

Liquet Versus New Catheter Configuration Cleared for Pulmonary Artery Pressure Measurement

February 24, 2026—Liquet Medical Inc. announced it has received a second FDA 510(k) clearance for a new configuration of its Versus catheter.

AHA/ACC Issue First Acute PE Guidelines With New Clinical Classification System

February 20, 2026—The American College of Cardiology (ACC)/American Heart Association (AHA) Joint Committee on Clinical Practice Guidelines and eight other professional societies released their first joint clinical practice guideline dedicated to the evaluation and management of acute pulmonary embolism (PE) in adults, introducing a new severity-based classification system and comprehensive recommendations spanning diagnosis, treatment, and follow-up care.

InVera Medical’s Venous Infusion Device Gains CE Mark

February 18, 2026—Irish medtech company InVera Medical announced the CE Mark approval of its InVera Infusion Device.

ALPHA-PE Research Fund Launched to Advance Pulmonary Embolism Care

February 5, 2026—AngioDynamics, Inc. and The PERT Consortium announced the launch of the ALPHA-PE Research Fund, an investigator-led initiative supporting independent pulmonary embolism (PE) research.

Nipro’s Avantec Vascular Gains FDA Clearance for Thrombectomy System

February 4, 2026—Avantec Vascular, a Nipro company, announced FDA 510(k) clearance of its thrombectomy system, which is intended for the treatment of thrombus in the peripheral venous system.

Penumbra Launches Lightning Flash 3.0 CAVT System to Treat VTE

January 26, 2026—Penumbra announced the launch of the Lightning Flash 3.0 computer assisted vacuum thrombectomy (CAVT) system for the treatment of venous thromboembolism (VTE).

Inquis Medical Raises Financing for Commercialization of Aventus Thrombectomy System

January 14, 2026—Inquis Medical, Inc., a privately held medical device company focused on mechanical thrombectomy for venous thromboembolic disease, announced the closing of a $75 million Series C financing round.